Legal Newsline

Saturday, March 28, 2020

Ark. SC overturns $1.2B verdict against Johnson & Johnson over Risperdal

By John O'Brien | Mar 20, 2014


LITTLE ROCK, Ark. (Legal Newsline) - The Arkansas Supreme Court has joined its neighbor in reversing a massive verdict against Johnson & Johnson over the prescription drug Risperdal.

On Thursday, the Supreme Court overturned a $1.2 billion verdict assessed by Pulaski County Circuit Court Judge Tim Fox in 2012. In Attorney General Dustin McDaniel's lawsuit, it was alleged that the company minimized health risks associated with the prescription antipsychotic in a letter sent to thousands of doctors in 2003.

It is the second bit of bad news this year for private attorneys hired by state attorneys general to pursue Risperdal cases. In January, the Louisiana Supreme Court struck down a $258 million verdict.

Risperdal is alleged to cause weight gain-related diseases like diabetes when it is taken, but Justice Karen R. Baker's majority opinion says it is considered "highly beneficial" in treating schizophrenia patients.

The State's case alleged Johnson & Johnson violated the Arkansas Medicaid Fraud False Claims Act and the Arkansas Deceptive Trade Practices Act.

Fox had ruled the company violated both and imposed the minimum statutory fine of $5,000 per violation on hundreds of thousands of violations.

The Supreme Court interpreted MFFCA to say only healthcare facilities can be liable for wrongdoing under it, and that Johnson & Johnson is not a healthcare facility.

As to the DTPA claim, Baker and the majority ruled Fox erred when he allowed a warning letter sent by the federal Food and Drug Administration to be admitted as evidence.

The letter said Johnson & Johnson's 2003 "Dear Healthcare Provider" letter failed to disclose certain health risks associated with Risperdal.

"(W)e note that for evidence to be admissible, it must be more probative than prejudicial," Baker wrote.

"Here, the 'Warning Letter' was highly prejudicial. The 'Warning Letter' was referred to repeatedly throughout the trial; in closing arguments alone it was mentioned at least 15 times."

Citing a previous case, Baker wrote, "Reports issued by governmental agencies, because of their 'official' nature, may well carry inordinate weight in the minds of jurors."

The verdict would have meant a windfall for private attorneys hired by McDaniel to pursue the case. After Fox made his $1.2 billion decision, he awarded attorneys at Houston-based Bailey Perrin Bailey $181 million in fees.

Courtney Hudson Goodson authored a two-page opinion on Johnson & Johnson's challenge of the attorneys fees award. It simply said that because the main judgment was reversed, the award of attorneys fees was reversed.

Bailey Perrin Bailey pushed Risperdal, Zyprexa and Seroquel cases around the country. Though no one at the firm contributed directly to McDaniel, Kenneth Bailey did give the Arkansas Democratic Party $70,000 in 2006.

Bailey Perrin Bailey did not represent Louisiana in its suit. In January, the Louisiana Supreme Court overturned a nearly $258 million verdict because the Attorney General's Office failed to establish sufficient facts to prove a cause of action under the state Medical Assistance Programs Integrity Law.

Previously, Johnson & Johnson had paid $181 million to settle any litigation with 37 attorneys general. Attorneys general who brought their own suits, like McDaniel and Charles Foti in Louisiana, have had varying levels of success with their individual claims.

Texas settled with the company for $158 million, though the State was expected to receive only $61 million. The rest will go to the federal government and a whistleblower.

A South Carolina judge assessed a penalty of $327 million, which has been appealed.

Massachusetts Attorney General Martha Coakley filed her own lawsuit in August 2011. The company won cases brought against it by West Virginia Attorney General Darrell McGraw and former Pennsylvania Gov. Ed Rendell.

Janssen, a subsidiary of Johnson & Johnson agreed to pay $2.2 billion to resolve federal criminal and civil investigations over the drug in November.

From Legal Newsline: Reach editor John O'Brien at

Want to get notified whenever we write about any of these organizations ?

Sign-up Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Louisiana Supreme CourtArkansas Supreme Court